Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylalanine SCHEMBL4970684 | 0.93 | ITGB3 (0.48) | ITGB3ITGA2BHDAC3HDAC4HDAC1 | |
| Lysine SCHEMBL28465641 | 0.89 | SLC15A2 (0.48) | ITGB3ITGA2BGSRSLC15A2THRB | |
| Lysine SCHEMBL1050579 | 0.89 | SLC15A2 (0.48) | ITGB3ITGA2BGSRSLC15A2THRB | |
| SCHEMBL29397843 | 0.89 | SLC15A2 (0.46) | ITGB3ITGA2BSLC15A2SIRT6SIRT1 | |
| SCHEMBL29396585 | 0.89 | SLC15A2 (0.46) | ITGB3ITGA2BSLC15A2SIRT6SIRT1 | |
| Lysine SCHEMBL28518498 | 0.88 | GSR (0.43) | ITGB3ITGA2BGSRSLC15A2THRB | |
| Lysine SCHEMBL28857873 | 0.88 | SLC15A2 (0.48) | ITGB3ITGA2BGSRSLC15A2THRB | |
| SCHEMBL30781142 | 0.88 | SLC15A2 (0.43) | ITGB3ITGA2BGSRSLC15A2HDAC3 | |
| SCHEMBL10525304 | 0.88 | SLC15A2 (0.43) | ITGB3ITGA2BGSRSLC15A2HDAC3 | |
| SCHEMBL30781070 | 0.88 | SLC15A2 (0.43) | ITGB3ITGA2BGSRSLC15A2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030215781-A1 | Protective solutions for organs | DR. FRANZ KOEHLER CHEMIE GMBH (DE) | 2003-11-20 | — | — | US | claimed |
| US-9603354-B2 | Protective solutions for organs | DR. FRANZ KOEHLER CHEMIE GMBH (DE) | 2017-03-28 | — | — | US | disclosed |
| US-7977383-B2 | Containing alkali ions, electrolytes, a buffer, polyol, saccharide and hydroxamic acid derivatives | DR. FRANZ KOEHLER CHEMIE GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20030215781-A1 | Protective solutions for organs | DR. FRANZ KOEHLER CHEMIE GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030215781-A1 | Protective solutions for organs | GLS, CA1, SI | ITGB3 2749/4885ITGA2B 3878/4885GSR 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.